|
Sign In to gain access to subscriptions and/or personal tools.
|
Double-Blind, Crossover Study of the Clinical Efficacy and the Hemorheological Effects of Pentoxifylline in Patients With Occlusive Arterial Disease of the Lower Limbs
A. Strano
Institute for General Clinical Medicine and Medical Therapeutics I, University of Palermo, Palermo, Italy
G. Davi
Institute for General Clinical Medicine and Medical Therapeutics I, University of Palermo, Palermo, Italy
G. Avellone
Institute for General Clinical Medicine and Medical Therapeutics I, University of Palermo, Palermo, Italy
S. Novo
Institute for General Clinical Medicine and Medical Therapeutics I, University of Palermo, Palermo, Italy
A. Pinto
Institute for General Clinical Medicine and Medical Therapeutics I, University of Palermo, Palermo, Italy
The effect of a 3 month daily administration of 800 mg pentoxifylline (Trental 400 bds) or placebo was assessed under double blind crossover design in 18 patients (12 males and 6 females) with peripheral occlusive arterial disease in respect of painfree walking distance and various hemorheological and hemostasiological variables, platelet aggregation, serum cholesterol and triglycerides. In first treatment period walking distance significantly increased with pentoxifylline by 46% from baseline 121 ± 15 m and by 4% with placebo from baseline 134 ± 18 m. Pentoxifylline administration furthermore yielded significant decrease in whole blood and plasma viscosity and significant increase in erythrocyte deformability. This was paralleled by distinct reduction of fibrinogen, platelet aggregation and euglobuline lysis time, also plethysmographic variables showed positive changes pointing to improvement of limb perfusion. The results of the study suggest that treatment of peripheral occlusive vascular disease by a drug improving blood fluidity through correction of hemorheological and hemostasiological factors turns especially promising and beneficial since the action centers finally on the languishing microcirculation in the ischemic tissue.
Angiology, Vol. 35, No. 7,
459-466 (1984)
DOI: 10.1177/000331978403500709
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Sobel and R. Verhaeghe
Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
815S - 843S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. P. Clagett, M. Sobel, M. R. Jackson, G. Y. H. Lip, M. Tangelder, and R. Verhaeghe
Antithrombotic Therapy in Peripheral Arterial Occlusive Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
609S - 626S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O. Ciocon, D. Galindo-Ciocon, D. J. Galindo, and J. O. Ciocon
A Comparison Between Aspirin and Pentoxifylline in Relieving Claudication Due to Peripheral Vascular Disease in the Elderly
Angiology,
March 1, 1997;
48(3):
237 - 240.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Panchenko, A. Eshkeeva, A. Dobrovolsky, E. Titaeva, Ya. Podinovskaya, K.M.A. Hussain, Yu. Karpov, and E. Panchenko
Effects of Indobufen and Pentoxifylline on Walking Capacity and Hemostasis in Patients with Intermittent Claudication: Results of Six Months of Treatment
Angiology,
March 1, 1997;
48(3):
247 - 254.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Ernst
Pentoxifylline for Intermittent Claudication: A Critical Review
Angiology,
May 1, 1994;
45(5):
339 - 345.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. J. Effeney, J. A. Stokes, and H. M. Trenerry
The Trials and Tribulations of Pentoxifylline
Perspectives in Vascular Surgery and Endovascular Therapy,
January 1, 1992;
5(2):
123 - 137.
[PDF]
|
|
|
|
|
|
|
D. M. Cummings and S. K. Ballas
Effects of Pentoxifylline and Metabolite on Red Blood Cell Deformability as Measured by Ektacytometry
Angiology,
February 1, 1990;
41(2):
118 - 123.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. De Felice, P. Gallo, and G. Masotti
Current Therapy of Peripheral Obstructive Arterial Disease. The Non-Surgical Approach
Angiology,
January 1, 1990;
41(1):
1 - 11.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Schneider
Results of Hemorheologically Active Treatment with Pentoxifylline in Patients with Cerebrovascular Disease
Angiology,
November 1, 1989;
40(11):
987 - 993.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. Rudofsky, K.F. Haussler, H.P. Kunkel, H. Schneider-May, F. Spengel, O. Symann, and H.-J. Werner
Intravenous Treatment of Chronic Peripheral Occlusive Arterial Disease: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial of Pentoxifylline
Angiology,
July 1, 1989;
40(7):
639 - 649.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. G. Dettori, M. Pini, A. Moratti, M. Paolicelli, P. Basevi, R. Quintavalla, C. Manotti, and C. Di Lecce
Acenocoumarol and Pentoxifylline in Intermittent Claudication. A Controlled Clinical Study
Angiology,
April 1, 1989;
40(4):
237 - 248.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. M. Nemiroff
Synergistic Effects of Pentoxifylline and Hyperbaric Oxygen on Skin Flaps
Arch Otolaryngol Head Neck Surg,
September 1, 1988;
114(9):
977 - 981.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. Koenig, E. Ernst, and A. Matrai
Blood Rheology Associated with Cardiovascular Risk Factors and Chronic Cardiovascular Diseases: Results of an Epidemiologic Cross-sectional Study
Angiology,
January 1, 1988;
39(11):
986 - 995.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. H. Schroer
Antithrombotic Potential of Pentoxifylline A Hemorheologically Active Drug
Angiology,
June 1, 1985;
36(6):
387 - 398.
[Abstract]
[PDF]
|
|
|
|
|
